期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 38, 期 25, 页码 2926-+出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.19.03123
关键词
-
类别
Since its approval in April 2018, osimertinib has been widely adopted as first-line therapy for patients with advancedEGFR-mutant non -small cell lung cancer (NSCLC). Understanding osimertinib resistance mechanisms and currently available treatment options are essential to selecting optimal second line therapy for patients whose disease progresses during front-line osimertinib. Using data compiled from 6 osimertinib-resistance series, we describe here the heterogeneous profile of EGFR-dependent and independent mechanisms of osimertinib treatment failure. We identifiedMETalterations (7%-24%),EGFRC797X (0%-29%), SCLC transformation (2%-15%), and oncogene fusions (1%-10%) as the most common mechanisms of resistance. This review provides an evidence-based, algorithmic approach to the evaluation and management of post-osimertinib progression as well as a compendium of active, enrolling clinical trials for this population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据